Who are Aptiom's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qualaquin, Septocaine, Ranocaine, Citanest, Peganone, Mesantoin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eslicarbazepine-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Aptiom — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aptiom (ESLICARBAZEPINE ACETATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: eslicarbazepine acetate. Area: Neuroscience.

marketed eslicarbazepine acetate Sodium channel alpha subunit Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Aptiom (ESLICARBAZEPINE ACETATE) — Sumitomo Pharma Am. Aptiom works by blocking sodium channels in the brain to reduce the frequency of seizures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aptiom TARGET	ESLICARBAZEPINE ACETATE	Sumitomo Pharma Am	marketed	eslicarbazepine acetate	Sodium channel alpha subunit	2013-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Septocaine	ARTICAINE		marketed	Amide Local Anesthetic	Sodium channel alpha subunits; brain (Types I, II, III)	2000-01-01
Ranocaine	PROPOXYCAINE HYDROCHLORIDE		marketed	propoxycaine	Sodium channel alpha subunits; brain (Types I, II, III)	1982-01-01
Citanest	PRILOCAINE		marketed	Amide Local Anesthetic [EPC]	Sodium channel alpha subunits; brain (Types I, II, III)	1965-01-01
Peganone	ETHOTOIN	Recordati	marketed	Anti-epileptic Agent	Sodium channel alpha subunit	1957-01-01
Mesantoin	MEPHENYTOIN	Novartis	marketed	Anti-epileptic Agent	Sodium channel alpha subunit	1946-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (eslicarbazepine acetate class)

Sumitomo Pharma Am · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aptiom — Competitive Intelligence Brief. https://druglandscape.com/ci/eslicarbazepine-acetate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab